中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 5
May  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(5): 942-947

Role and mechanism of T helper 17 cells/regulatory T cells immune balance regulated by the TGF-‍β1/Smad signaling pathway mediated in nonalcoholic steatohepatitis

DOI: 10.12449/JCH250521
  • 1.

    The Second Clinical Medical School of Guizhou University of Traditional Chinese Medicine，Guiyang 550002，China

  • 2a.

    Department of Clinical Laboratory，The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine，Guiyang 550001，China

  • 2b.

    Department of Gastroenterology，The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine，Guiyang 550001，China

Research funding:

National Natural Science Foundation of China (82160866);

Science and Technology Plan Project of Guizhou Province （Guizhou Science and Technology base-ZK ［2023］ General 433） ;

Science and Technology Fund of Guizhou Provincial Health Commission (gzwkj2023-208);

Key Laboratory of Higher Education in Guizhou Province （Guizhou Education Technology ［2023］017） 

More Information
  • Corresponding author: YANG Mei， 908417289@qq.com （ORCID： 0009-0003-3563-4767）
  • Received Date: 2024-09-09
  • Accepted Date: 2024-10-22
  • Published Date: 2025-05-25
    Abstract
  • Nonalcoholic steatohepatitis （NASH） is a chronic metabolic disease characterized by hepatocyte fatty degeneration and ballooning degeneration， and it plays an important role in the progression of hepatic steatosis. Recent studies have shown that immune homeostasis imbalance between T helper 17 （Th17） and regulatory T （Treg） cells are closely associated with the pathological process of NASH. Transforming growth factor-β1 （TGF-β1） is a key cytokine for regulating the differentiation and proliferation of Th17/Treg cells， and TGF-β1 binds to its receptor and activates the Smad signaling pathway， thereby regulating the immune balance of Th17/Treg cells and the expression of inflammatory factors and participating in the repair of liver inflammation. This article systematically reviews the molecular mechanism of the TGF-β1/Smad signaling pathway in affecting NASH by regulating the immune balance of Th17/Treg cells， in order to provide a theoretical basis for the research on the pathogenesis of NASH and related treatment strategies.

     

    • FullText(HTML)
  • loading
    • References(45)
  • [1]
    TARANTINO G. NAFLD or MAFLD: That is the conundrum[J]. Hepatobiliary Pancreat Dis Int, 2022, 21( 2): 103- 105. DOI: 10.1016/j.hbpd.2022.01.008.
    [2]
    TIAN AP, YANG YF. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology[J]. J Clin Hepatol, 2023, 39( 3): 491- 497. DOI: 10.3969/j.issn.1001-5256.2023.03.002.

    田爱平, 杨永峰. 非酒精性脂肪性肝病诊断: 病理的重要性[J]. 临床肝胆病杂志, 2023, 39( 3): 491- 497. DOI: 10.3969/j.issn.1001-5256.2023.03.002.
    [3]
    MARJOT T, RAY DW, TOMLINSON JW. Is it time for chronopharmacology in NASH?[J]. J Hepatol, 2022, 76( 5): 1215- 1224. DOI: 10.1016/j.jhep.2021.12.039.
    [4]
    HUANG DQ, EL-SERAG HB, LOOMBA R. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 4): 223- 238. DOI: 10.1038/s41575-020-00381-6.
    [5]
    CHEN H, ZHOU Y, HAO HP, et al. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies[J]. Chin J Nat Med, 2024, 22( 8): 724- 745. DOI: 10.1016/S1875-5364(24)60690-4.
    [6]
    HUBY T, GAUTIER EL. Immune cell-mediated features of non-alcoholic steatohepatitis[J]. Nat Rev Immunol, 2022, 22( 7): 429- 443. DOI: 10.1038/s41577-021-00639-3.
    [7]
    LI L, LI SH, JIANG JP, et al. Investigating pharmacological mechanisms of andrographolide on non-alcoholic steatohepatitis(NASH): A bioinformatics approach of network pharmacology[J]. Chin Herb Med, 2021, 13( 3): 342- 350. DOI: 10.1016/j.chmed.2021.05.001.
    [8]
    UNGER LW, HERAC M, STAUFER K, et al. The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: A retrospective case-control study[J]. Eur J Gastroenterol Hepatol, 2017, 29( 3): 309- 316. DOI: 10.1097/MEG.0000000000000794.
    [9]
    DENG ZQ, FAN T, XIAO C, et al. TGF-β signaling in health, disease, and therapeutics[J]. Signal Transduct Target Ther, 2024, 9( 1): 61. DOI: 10.1038/s41392-024-01764-w.
    [10]
    KUMAR R, THEISS AL, VENUPRASAD K. ROR-γt protein modifications and IL-17-mediated inflammation[J]. Trends Immunol, 2021, 42( 11): 1037- 1050. DOI: 10.1016/j.it.2021.09.005.
    [11]
    WU B, WAN YS. Molecular control of pathogenic Th17 cells in autoimmune diseases[J]. Int Immunopharmacol, 2020, 80: 106187. DOI: 10.1016/j.intimp.2020.106187.
    [12]
    LI N, YAMAMOTO G, FUJI H, et al. Interleukin-17 in liver disease pathogenesis[J]. Semin Liver Dis, 2021, 41( 4): 507- 515. DOI: 10.1055/s-0041-1730926.
    [13]
    CHEN L, ZHAO Q, YANG M, et al. Effects of Quzhi Yugan decoction on IL-17 and IL-2 in NASH rats based on JAK2-STAT3 signaling pathway[J]. Liaoning J Tradit Chin Med, 2023, 50( 8): 215- 220, 257. DOI: 10.13192/j.issn.1000-1719.2023.08.058.

    陈亮, 赵琦, 杨梅, 等. 基于JAK2-STAT3信号通路探讨祛脂愈肝对NASH模型大鼠IL-17、IL-2的影响[J]. 辽宁中医杂志, 2023, 50( 8): 215- 220, 257. DOI: 10.13192/j.issn.1000-1719.2023.08.058.
    [14]
    SINGER M, ELSAYED AM, HUSSEINY MI. Regulatory T-cells: The face-off of the immune balance[J]. Front Biosci(Landmark Ed), 2024, 29( 11): 377. DOI: 10.31083/j.fbl2911377.
    [15]
    WING JB, TANAKA A, SAKAGUCHI S. Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer[J]. Immunity, 2019, 50( 2): 302- 316. DOI: 10.1016/j.immuni.2019.01.020.
    [16]
    VELLIOU RI, MITROULIS I, CHATZIGEORGIOU A. Neutrophil extracellular traps contribute to the development of hepatocellular carcinoma in NASH by promoting Treg differentiation[J]. Hepatobiliary Surg Nutr, 2022, 11( 3): 415- 418. DOI: 10.21037/hbsn-21-557.
    [17]
    HE BH, WU LY, XIE W, et al. The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice[J]. BMC Immunol, 2017, 18( 1): 33. DOI: 10.1186/s12865-017-0215-y.
    [18]
    CHACKELEVICIUS CM, GAMBARO SE, TIRIBELLI C, et al. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis[J]. World J Gastroenterol, 2016, 22( 41): 9096- 9103. DOI: 10.3748/wjg.v22.i41.9096.
    [19]
    ZHANG DJ, HOU J. Research advances in regulation of non-alcoholic steatohepatitis by liver immune cells[J]. Chin J Immun, 2025, 41( 2): 461- 466. DOI: 10.3969/j.issn.1000-484X.2025.02.035.

    张丁吉, 侯晋. 肝脏免疫细胞调控非酒精性脂肪性肝炎的研究进展[J]. 中国免疫学杂志, 2025, 41( 2): 461- 466. DOI: 10.3969/j.issn.1000-484X.2025.02.035.
    [20]
    LI KY, ZHAO Q, HUANG J, et al. The role of Th17/Treg balance in non-alcoholic fatty liver disease[J]. Chin J Clin, 2024, 52( 6): 638- 641. DOI: 10.3969/j.issn.2095-8552.2024.06.003.

    李开楊, 赵琦, 黄敬, 等. Th17/Treg平衡在非酒精性脂肪性肝病中的作用[J]. 中国临床医生杂志, 2024, 52( 6): 638- 641. DOI: 10.3969/j.issn.2095-8552.2024.06.003.
    [21]
    SUN L, LI B, QIU HK, et al. Significance of TH17/Treg cells in peripheral blood of patients with nonalcoholic fatty liver disease[J]. Chin J Integr Tradit West Med Dig, 2019, 27( 11): 858- 861. DOI: 10.3969/j.issn.1671-038X.2019.11.13.

    孙亮, 李博, 邱厚匡, 等. 非酒精性脂肪性肝病患者外周血TH17/Treg细胞的变化及意义[J]. 中国中西医结合消化杂志, 2019, 27( 11): 858- 861. DOI: 10.3969/j.issn.1671-038X.2019.11.13.
    [22]
    YUAN YL, MAO TY, HAN HX, et al. Study on the mechanism of Yinchen Linggui Zhugan Decoction regulating Th17/Treg immune balance in nonalcoholic fatty liver disease mice[J]. Chin J Integr Tradit West Med Dig, 2024, 32( 2): 139- 144. DOI: 10.3969/j.issn.1671-038X.2024.02.10.

    袁亚利, 毛堂友, 韩海啸, 等. 茵陈苓桂术甘汤对非酒精性脂肪性肝病Th17/Treg细胞免疫平衡的影响[J]. 中国中西医结合消化杂志, 2024, 32( 2): 139- 144. DOI: 10.3969/j.issn.1671-038X.2024.02.10.
    [23]
    JUNG HJ, CHO K, KIM SY, et al. Ethanol extract of Pharbitis nil ameliorates liver fibrosis through regulation of the TGFβ1-SMAD2/3 pathway[J]. J Ethnopharmacol, 2022, 294: 115370. DOI: 10.1016/j.jep.2022.115370.
    [24]
    SCHMIDT A, ÉLIÁS S, JOSHI RN, et al. In vitro differentiation of human CD4+FOXP3+ induced regulatory T cells(iTregs) from Naïve CD4+ T cells using a TGF-β-containing protocol[J]. J Vis Exp, 2016( 118): 55015. DOI: 10.3791/55015.
    [25]
    SUN GY, WEI YX, ZHU JJ, et al. The transcription factor T-bet promotes the pathogenesis of nonalcoholic fatty liver disease by upregulating intrahepatic inflammation[J]. Biochem Biophys Res Commun, 2023, 682: 266- 273. DOI: 10.1016/j.bbrc.2023.10.014.
    [26]
    GHORESCHI K, LAURENCE A, YANG XP, et al. Generation of pathogenic Th17 cells in the absence of TGF-β signalling[J]. Nature, 2010, 467( 7318): 967- 971. DOI: 10.1038/nature09447.
    [27]
    PAWLAK JB, BLOBE GC. TGF-β superfamily co-receptors in cancer[J]. Dev Dyn, 2022, 251( 1): 137- 163. DOI: 10.1002/dvdy.338.
    [28]
    HATA A, CHEN YG. TGF-β signaling from receptors to smads[J]. Cold Spring Harb Perspect Biol, 2016, 8( 9): a022061. DOI: 10.1101/cshperspect.a022061.
    [29]
    MIYAZAWA K, MIYAZONO K. Regulation of TGF-β family signaling by inhibitory Smads[J]. Cold Spring Harb Perspect Biol, 2017, 9( 3): a022095. DOI: 10.1101/cshperspect.a022095.
    [30]
    LEE H, YU DM, BAHN MS, et al. Hepatocyte-specific Prominin-1 protects against liver injury-induced fibrosis by stabilizing SMAD7[J]. Exp Mol Med, 2022, 54( 8): 1277- 1289. DOI: 10.1038/s12276-022-00831-y.
    [31]
    TZAVLAKI K, MOUSTAKAS A. TGF-β signaling[J]. Biomolecules, 2020, 10( 3): 487. DOI: 10.3390/biom10030487.
    [32]
    MONTELEONE G, LAUDISI F, STOLFI C. Smad7 as a positive regulator of intestinal inflammatory diseases[J]. Curr Res Immunol, 2023, 4: 100055. DOI: 10.1016/j.crimmu.2023.100055.
    [33]
    SONG Y, WEI JY, LI R, et al. Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-β/SMAD signaling[J]. Hepatology, 2023, 78( 5): 1433- 1447. DOI: 10.1097/HEP.0000000000000319.
    [34]
    WAN ZK, ZHOU ZF, LIU Y, et al. Regulatory T cells and T helper 17 cells in viral infection[J]. Scand J Immunol, 2020, 91( 5): e12873. DOI: 10.1111/sji.12873.
    [35]
    FRICK CL, YARKA C, NUNNS H, et al. Sensing relative signal in the tgf-β/smad pathway[J]. Proc Natl Acad Sci U S A, 2017, 114( 14): E2975- E2982. DOI: 10.1073/pnas.1611428114.
    [36]
    XU Q, JIN XX, ZHENG MZ, et al. Phosphatase PP2A is essential for TH17 differentiation[J]. Proc Natl Acad Sci U S A, 2019, 116( 3): 982- 987. DOI: 10.1073/pnas.1807484116.
    [37]
    CHEN T, ZHU C, WANG X, et al. Asiatic acid encapsulated exosomes of hepatocellular carcinoma inhibit epithelial-mesenchymal transition through transforming growth factor beta/smad signaling pathway[J]. J Biomed Nanotechnol, 2021, 17( 12): 2338- 2350. DOI: 10.1166/jbn.2021.3208.
    [38]
    HE W, DORN DC, ERDJUMENT-BROMAGE H, et al. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway[J]. Cell, 2006, 125( 5): 929- 941. DOI: 10.1016/j.cell.2006.03.045.
    [39]
    QIN G, WANG GZ, GUO DD, et al. Deletion of Smad4 reduces hepatic inflammation and fibrogenesis during nonalcoholic steatohepatitis progression[J]. J Dig Dis, 2018, 19( 5): 301- 313. DOI: 10.1111/1751-2980.12599.
    [40]
    YAN X, LIAO H, CHENG M, et al. Smad7 protein interacts with receptor-regulated Smads(R-Smads) to inhibit transforming growth factor-β(TGF-β)/Smad signaling[J]. J Biol Chem, 2016, 291( 1): 382- 392. DOI: 10.1074/jbc.M115.694281.
    [41]
    ZHANG TT, WEN F, WU YN, et al. Cross-talk between TGF-beta/SMAD and integrin signaling pathways in regulating hypertrophy of mesenchymal stem cell chondrogenesis under deferral dynamic compression[J]. Biomaterials, 2015, 38: 72- 85. DOI: 10.1016/j.biomaterials.2014.10.010.
    [42]
    PENG DD, FU MY, WANG MN, et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy[J]. Mol Cancer, 2022, 21( 1): 104. DOI: 10.1186/s12943-022-01569-x.
    [43]
    ZHANG SP, HE Y, XU T, et al. Regulatory effects of total triterpenoid of Prunella vulgaris On activities of ERK and TGF-β1/Smad signaling pathway in protecting hepatic fibrosis in rats[J]. Chin Pharmacol Bull, 2015, 31( 2): 261- 266. DOI: 10.3969/j.issn.1001-1978.2015.02.023.
    [44]
    GU AD, WANG YQ, LIN L, et al. Requirements of transcription factor Smad-dependent and-independent TGF-β signaling to control discrete T-cell functions[J]. Proc Natl Acad Sci U S A, 2012, 109( 3): 905- 910. DOI: 10.1073/pnas.1108352109.
    [45]
    DINARVAND N, AFARIN R, SHAKERIAN E, et al. The effect of saraglitazar on TGF-β-induced smad3 phosphorylation and expression of genes related to liver fibrosis in LX2 cell line[J]. Mol Biol Rep, 2024, 51( 1): 541. DOI: 10.1007/s11033-024-09443-3.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (534) PDF downloads(33) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return